Blithe D L, Caron P J, Louvet J P, Nisula B C
Endocrinology. 1986 Nov;119(5):2270-8. doi: 10.1210/endo-119-5-2270.
We devised an in vivo biological assay for ovarian growth inhibiting activity to examine extracts of human pregnancy urine for the presence of ovarian growth inhibiting factor. Diethylstilbestrol (DES) capsules were implanted sc in immature hypophysectomized female rats; FSH was injected sc with or without test substance for 5 days. Rats with unstimulated ovaries were implanted with blank capsules and given the vehicle without FSH. Twenty four hours after the last injection, the ovaries were removed and weighed. The ovarian growth inhibition of the ovarian weight gain achieved in rats treated with DES and FSH. Crude commercial human CG (hCG) preparations, extracted from pregnancy urine, were chromatographed on Sephadex G-100, and the fractions were tested for ovarian growth inhibiting activity. The peak of ovarian growth inhibiting activity was found in fractions eluting from the column in the mol wt range of 12,000-20,000. Ovarian growth inhibiting activity was heat sensitive, not extracted by ether, and precipitated by acetone. Ovarian growth inhibiting activity was stable in acid at pH 2, but was inactivated by digestion with trypsin. The ovarian growth inhibiting activity was purified by chromatography on Concanavalin A-Sepharose and diethylaminoethyl-Sephacel. The active material contained hCG alpha, hCG beta, and beta-carboxyterminal peptide-immunoreactivity and its inhibiting activity could be removed from solution by immunoadsorption with antisera specific for hCG beta. The ovarian growth inhibiting activity was further purified on an anti-hCG alpha-immunoglobulin G affinity column. The activity was eluted from the affinity column at low pH, and eluted material contained all of the immunodeterminants of hCG. Virtually identical dose-response curves of ovarian inhibition were obtained using equivalent doses of beta-carboxyterminal peptide immunoreactivity of purified inhibitor and purified hCG (CR123). The inhibiting activity reached plateau of 80-90% at doses of 50-100 ng hCG/rat. Upon rechromatography on Sephadex G-100, the ovarian growth activity that was pooled from fractions corresponding to the 12,000-20,000 mol wt range was recovered in fractions corresponding to the elution position of hCG. We conclude that the low mol wt inhibiting activity observed in the crude pregnancy extracts is due to hCG and that hCG is a very potent inhibitor of FSH/DES stimulation of ovarian growth.
我们设计了一种用于检测卵巢生长抑制活性的体内生物学检测方法,以检查人妊娠尿液提取物中是否存在卵巢生长抑制因子。将己烯雌酚(DES)胶囊皮下植入未成熟的垂体切除雌性大鼠体内;皮下注射促卵泡激素(FSH),同时或不同时注射受试物质,持续5天。未受刺激卵巢的大鼠植入空白胶囊,并给予不含FSH的赋形剂。在最后一次注射24小时后,取出卵巢并称重。检测DES和FSH处理的大鼠卵巢重量增加所实现的卵巢生长抑制情况。从妊娠尿液中提取的粗制商业人绒毛膜促性腺激素(hCG)制剂在葡聚糖凝胶G - 100上进行色谱分析,并对各组分进行卵巢生长抑制活性检测。在分子量范围为12,000 - 20,000从柱中洗脱的组分中发现了卵巢生长抑制活性峰。卵巢生长抑制活性对热敏感,不被乙醚提取,可被丙酮沉淀。卵巢生长抑制活性在pH 2的酸性条件下稳定,但可被胰蛋白酶消化而失活。通过伴刀豆球蛋白A - 琼脂糖和二乙氨基乙基 - 葡聚糖凝胶色谱法对卵巢生长抑制活性进行纯化。活性物质含有hCGα、hCGβ和β - 羧基末端肽免疫反应性,其抑制活性可通过用针对hCGβ的抗血清进行免疫吸附从溶液中去除。在抗hCGα - 免疫球蛋白G亲和柱上进一步纯化卵巢生长抑制活性。活性在低pH下从亲和柱上洗脱,洗脱物质含有hCG的所有免疫决定簇。使用等量的纯化抑制剂的β - 羧基末端肽免疫反应性和纯化的hCG(CR123)获得了几乎相同的卵巢抑制剂量 - 反应曲线。在剂量为50 - 100 ng hCG/大鼠时,抑制活性达到80 - 90%的平台期。在葡聚糖凝胶G - 100上重新进行色谱分析时,从对应于12,000 - 20,000分子量范围的组分中汇集的卵巢生长活性在对应于hCG洗脱位置的组分中得以恢复。我们得出结论,在粗制妊娠提取物中观察到的低分子量抑制活性是由于hCG,并且hCG是FSH/DES刺激卵巢生长的一种非常有效的抑制剂。